FP
AVNS icon

Foundry Partners’s Avanos Medical AVNS Stock Holding History

Foundry Partners’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-119,870
Closed -$1.91M – 263
2024
Q4 		$1.91M Sell
119,870
-43,160
-26% -$854K 0.1% 209
2024
Q3 		$3.92M Buy
163,030
+1,800
+1% +$41.1K 0.19% 172
2024
Q2 		$3.21M Sell
161,230
-2,025
-1% -$39.4K 0.17% 175
2024
Q1 		$3.25M Sell
163,255
-207,774
-56% -$4.02M 0.17% 183
2023
Q4 		$8.32M Buy
371,029
+158,473
+75% +$3.27M 0.5% 53
2023
Q3 		$4.3M Buy
212,556
+39,068
+23% +$886K 0.27% 124
2023
Q2 		$4.43M Buy
173,488
+43,868
+34% +$1.16M 0.27% 108
2023
Q1 		$3.85M Buy
129,620
+120,200
+1,276% +$3.49M 0.24% 130
2022
Q4 		$255K Sell
9,420
-220
-2% -$5.38K 0.01% 287
2022
Q3 		$210K Sell
9,640
-185
-2% -$4.83K 0.01% 305
2022
Q2 		$269K Hold
9,825
– – 0.02% 273
2022
Q1 		$329K Buy
+9,825
New +$316K 0.02% 293

Other funds holding AVNS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Foundry Partners's AVNS Position: Q1 2025 in Review

Foundry Partners sold out of Avanos Medical (AVNS) in Q1 2025, closing a stake of 119,870 shares — an estimated $1.91M sold.

Foundry Partners first reported a position in AVNS in Q1 2022 and held it in 12 quarters. The position peaked at $8.32M in Q4 2023. 277 funds tracked by Wall St. Rank hold AVNS as of Q1 2025.

  • Foundry Partners reported no remaining Avanos Medical position as of Q1 2025 after selling out during the quarter.
  • Foundry Partners sold 119,870 Avanos Medical shares in Q1 2025, an estimated $1.91M.
  • Foundry Partners first reported a position in Avanos Medical in Q1 2022 and held it in 12 quarters.
  • Foundry Partners's Avanos Medical position peaked at $8.32M in Q4 2023.
  • 277 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2025.

Based on Foundry Partners's 13F filing for Q1 2025, filed 5 May 2025.